Loading clinical trials...
Loading clinical trials...
Indications for and Experience With the Wearable Cardioverter Defibrillator (WCD) - Austrian WCD Registry
Background: The wearable cardioverter defibrillator (WCD) is an established treatment option for patients at high risk for ventricular tachycardia / ventricular fibrillation (VT/VF), either in whom this risk may only be temporarily present, or in patients at high risk for sudden cardiac death (SCD) or after VT/VF in whom an implantable cardioverter defibrillator (ICD is currently not possible for other reasons (infection, recent MI \<40days, recent PCI/CABG \< 3months etc.). Methods: Comprehensive registry including all patients in Austria who received a WCD in 2010-2016.
Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
Age
All ages
Sex
ALL
Healthy Volunteers
No
Medical University of Graz/ Division of Cardiology
Graz, Austria
Start Date
November 1, 2014
Primary Completion Date
December 1, 2021
Completion Date
March 1, 2022
Last Updated
September 14, 2021
450
ESTIMATED participants
Registry
OTHER
Lead Sponsor
Medical University of Graz
NCT07484009
NCT07191730
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions